💊 GLP-1 Drugs
Ozempic vs Saxenda — Which Is Better for Weight Loss? (2026)
Full comparison of Ozempic (semaglutide) and Saxenda (liraglutide) for weight loss — effectiveness, side effects, cost, and availability. Updated January 2026.
Key Takeaways
- Ozempic/Wegovy produces 3× more weight loss than Saxenda — 15% vs 5–8%
- Saxenda requires daily injections while Ozempic is once-weekly — major convenience advantage
- Saxenda was the first approved GLP-1 drug for obesity (2014) — now largely superseded
- Saxenda costs significantly less than Ozempic/Wegovy in private market
- Both cause similar GI side effects — nausea, vomiting, diarrhoea
Two Drugs, Same Mechanism — Very Different Results
Both Saxenda (liraglutide 3mg) and Ozempic/Wegovy (semaglutide) are GLP-1 receptor agonists — but they differ significantly in their molecular structure, dosing frequency, and clinical effectiveness. Saxenda was the pioneer approved weight loss GLP-1 drug; semaglutide has largely superseded it due to superior efficacy.
5–8%
Average weight loss with Saxenda (SCALE trials)
15–17%
Average weight loss with Wegovy (STEP trials)
Daily vs Weekly
Saxenda injection frequency vs Ozempic/Wegovy
Head-to-Head Comparison
| Feature | Saxenda (Liraglutide 3mg) | Ozempic/Wegovy (Semaglutide) |
|---|---|---|
| Weight loss average | 5–8% | 15–17% |
| Injection frequency | Daily | Once weekly |
| CVD outcome data | LEADER trial — modest | SELECT trial — 20% CVD reduction |
| UK NHS availability | Limited, largely phased out | Wegovy — specialist pathway |
| Private cost (UK/month) | £80–150 | £180–280 |
| Approved for T2D? | Victoza (1.2–1.8mg only) | Ozempic — yes |
| Approved for obesity? | Yes (Saxenda) | Yes (Wegovy) |
| Side effects profile | GI — nausea similar | GI — similar but slightly better tolerated |
When Saxenda Might Still Be Chosen
- Cost: Saxenda is available at lower cost privately — useful when budget is the primary constraint
- Supply: When Wegovy/Ozempic is unavailable due to supply constraints, Saxenda may be available as an alternative
- Doctor preference: Some prescribers have more experience with liraglutide and prefer it for specific patient groups
- Missed doses: Saxenda's shorter half-life means missed doses have less impact on pharmacology (though more frequent dosing makes missing more likely)
⚠️ Clinical Recommendation in 2026
For most patients requiring pharmacological weight management, semaglutide (Wegovy) or tirzepatide (Mounjaro) are now preferred over liraglutide (Saxenda) due to significantly greater efficacy and better cardiovascular outcome data. Saxenda retains a niche role where cost is a limiting factor or when the newer agents are contraindicated or unavailable.Frequently Asked Questions
Is Saxenda still available on the NHS?▼
Saxenda (liraglutide 3mg) was available through NHS specialist weight management services but has been largely superseded by Wegovy (semaglutide). NICE now recommends Wegovy as the preferred GLP-1 drug for obesity. Saxenda may still be available privately or in some NHS settings where Wegovy supply is limited. Check with your GP or weight management service for current availability.
Why did my doctor prescribe Saxenda instead of Ozempic?▼
Possible reasons: cost (Saxenda is cheaper privately), formulary availability at their practice, prior experience with liraglutide, or specific clinical considerations. If you want to discuss switching to Wegovy (semaglutide) for better efficacy, have that conversation with your prescriber — the switch is straightforward and well-established.
Can I switch from Saxenda to Ozempic or Wegovy?▼
Yes — switching is common as Wegovy becomes more available. When switching from Saxenda to Wegovy, the transition is made at the point of Saxenda discontinuation (no washout needed — both are GLP-1 agonists). Start Wegovy at the lowest dose (0.25mg) regardless of your Saxenda dose and titrate up to the therapeutic dose over the standard escalation schedule.
Related Health Guides
Article
Wegovy Complete Guide
Article
Mounjaro vs Ozempic
Article
All GLP-1 Drugs
Calculator
BMI Calculator
⚕️ Medical Disclaimer: For informational purposes only. Always consult a qualified healthcare professional before starting or changing any medication or treatment.
Dr
Dr. Priya Sharma, MD
WellCalc Medical Contributor
All articles reviewed by qualified healthcare professionals following NHS, AHA, and WHO guidelines.